Miami, Florida —CELLGENIC, a division of Global Stem Cells Group and a recognized name in regenerative medicine, is pleased to announce the successful introduction of its Peptide Pen product line, officially presented during the Global Stem Cells Group Global Summit held in Cancún. The new line represents an important step toward simplifying and modernizing peptide therapy within the field of regenerative and longevity medicine.
The CELLGENIC Peptide Pen series was designed to offer physicians a more practical approach to peptide therapy. Each pre-loaded device contains synergistic peptide formulations that we believe may support various clinical goals such as recovery, immune balance, metabolic optimization, and overall wellness. By integrating multiple compounds into a single, ready-to-use pen, we hope to help physicians streamline their protocols while maintaining consistency and ease of use.
“Our mission has always been to make advanced biologics more accessible and clinically practical,” said Benito Novas, Founder of Global Stem Cells Group. “We believe the Peptide Pen line reflects this philosophy by providing a convenient and reliable tool for physicians dedicated to regenerative and performance medicine.”
Since its debut at the Global Summit, the Peptide Pen line has received encouraging interest from physicians attending the event and from CELLGENIC’s international partners. The company believes this positive reception reflects the growing recognition of peptide-based approaches within medical practice.
“We are very encouraged by the response from physicians who attended the Summit,” said Sarah Barroso, Managing Director of CELLGENIC. “We expect the Peptide Pen to continue generating interest among professionals seeking innovative yet practical tools to integrate into their existing clinical programs.”
A Growing Movement in Modern Medicine
Across the world, peptide therapy is gaining attention among physicians who seek to work at the intersection of biology, longevity, and personalized medicine. These short chains of amino acids are being studied for their potential roles in supporting cellular repair, optimizing metabolism, and promoting balanced physiological function.
At CELLGENIC, we believe peptide therapy represents one of the most promising frontiers in the evolution of regenerative and preventive medicine. As healthcare continues to shift toward individualized and performance-based care, peptide integration may help physicians design more targeted and adaptive therapeutic programs.
Through innovation and education, we hope to contribute to this global movement by offering tools that are practical, well-supported, and aligned with responsible medical practice.
Commitment to Education and Ethical Practice
The launch of the Peptide Pen line also aligns with CELLGENIC’s ongoing educational mission through the International Society for Stem Cell Application (ISSCA), which continues to promote physician training in advanced biologic and peptide-based therapies.
CELLGENIC sells its products exclusively to licensed physicians and medical professionals, ensuring that all peptide applications remain within a qualified and ethical clinical framework.
Through this initiative, CELLGENIC continues to expand its presence in regenerative medicine, maintaining a focus on innovation, education, and international collaboration.
About CELLGENIC
CELLGENIC, a division of Global Stem Cells Group, focuses on the development and distribution of advanced biologic products including exosomes, cell-based systems, and peptide solutions. With more than 15 years of experience, CELLGENIC aims to support physicians worldwide through innovation, training, and reliable access to next-generation medical technologies.
About Global Stem Cells Group and CELLGENIC
Founded in 2010 and headquartered in Miami, USA, Global Stem Cells Group (GSCG) is a biotechnology consortium with a presence in more than 40 countries. The organization brings together clinical research, physician education, and biologics development under one umbrella.
Its flagship brand, CELLGENIC, offers a portfolio of regenerative medicine products—including exosomes, MSCs, and platelet-rich plasma kits—produced under rigorous quality protocols. Through ISSCA, its educational division, GSCG provides certification programs, workshops, and international conferences that are expected to support the responsible adoption of regenerative therapies.
Global Stem Cells Group is a subsidiary to our publicly traded company, Regenerative Medical Technology Group Inc., operating under the symbol RMTG.
More information:
www.stemcellsgroup.com | www.issca.us
Safe Harbor Statement:
Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions, including those related to expansion efforts into the Dominican Republic. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
